# SGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in Diabetes

Study · id `cardio:ct-nct07614230` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07614230](<https://clinicaltrials.gov/study/NCT07614230>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07614230

Browse, organ or system: Heart; Blood vessels; Metabolism  
Browse, condition area: Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 144 participants.

## Technical summary

Registry record NCT07614230. Randomized; no masking; primary purpose treatment. Start 2026-01-01 (actual); primary completion 2027-06-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 144 participants (planned count; ClinicalTrials.gov record NCT07614230, source copy `cardio:ctgov-nct07614230-2026-05-29`, retrieved 2026-10-26)
- Started: 2026-01-01 (actual) (ClinicalTrials.gov record NCT07614230, source copy `cardio:ctgov-nct07614230-2026-05-29`, retrieved 2026-10-26)
- Primary completion: 2027-06-01 (anticipated) (ClinicalTrials.gov record NCT07614230, source copy `cardio:ctgov-nct07614230-2026-05-29`, retrieved 2026-10-26)
- Completion: 2028-12-31 (anticipated) (ClinicalTrials.gov record NCT07614230, source copy `cardio:ctgov-nct07614230-2026-05-29`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07614230, source copy `cardio:ctgov-nct07614230-2026-05-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07614230-2026-05-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: SGLT2 Inhibitors on Coronary Atherosclerosis Progression Via Perivascular Adipose Tissue in Diabetes
- Acronym: SCOPE
- Condition: Type 2 Diabetes Mellitus (T2DM)
- Condition: Coronary Artery Disease
- Condition: Atherosclerosis
- Intervention (Drug): Dapagliflozin (DAPA)
- Intervention (Other): Standard Care (Treatment as Usual)
- Lead sponsor: Junjie Yang
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Dapagliflozin (`cardio:dapagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)

## Provenance

Content hash: 1fe44020515392eb808e4a4ddf3ce6017caf2642a4f4582429577e3abef58862
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
